Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

23 September 2021

Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COV..

22 September 2021

Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Addit..

20 September 2021

Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COV..

Press releases (more)

Upcoming Events

September 27, 2021 from 8:40 AM to 9:10 AM EDT

Cantor Virtual Global Healthcare Conference

November 9, 2021 at 8:00 AM EST

Third Quarter 2021 Earnings Call

Upcoming events (more)

Stock Quote

Sep 26, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.